Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting

Katharine A. Rendle, Mark Schiffman, Li C. Cheung, Walter K. Kinney, Barbara Fetterman, Nancy E. Poitras, Thomas Lorey, Philip E. Castle

Research output: Contribution to journalArticle

Abstract

Although guidelines have recommended extended interval cervical screening using concurrent human papillomavirus (HPV) and cytology (“cotesting”) for over a decade, little is known about its adoption into routine care. Using longitudinal medical record data (2003–2015) from Kaiser Permanente Northern California (KPNC), which adopted triennial cotesting in 2003, we examined adherence to extended interval screening. We analyzed predictors of screening intervals among 491,588 women undergoing routine screening, categorizing interval length into early (< 2.5 years), adherent (2.5 < 3.5 years), or late (3.5 < 6.0 years). We also examined repeated early screening in a subgroup of 50,691 women. Predictors examined included: cohort year (defined by baseline cotest, 2003–2009), race/ethnicity, and baseline age. Compared to the 2003 cohort, women in the 2009 cohort were significantly less likely to screen early (aOR = 0.22, 95% CI = 0.21, 0.23) or late (aOR = 0.47, 95% CI = 0.45, 0.49). African American (AA) and Hispanic women were less adherent overall than Non-Hispanic White women, with increased early [(AA: aOR = 1.21, 95%CI = 1.17, 1.25) (Hispanic: aOR = 1.08, 95%CI = 1.06, 1.11)] and late screening [(AA: aOR = 1.23, 95%CI = 1.19, 1.27) (Hispanic: aOR = 1.06, 95%CI = 1.03, 1.08)]. Asian women were slightly more likely to screen early (aOR = 1.03, 95%CI = 1.01, 1.05), and less likely to screen late (aOR = 0.92, 95% CI = 0.90, 0.94). Women aged 60–64 years were most likely to screen early for two consecutive intervals (aOR = 2.09, 95%CI = 1.91, 2.29). Our study found that widespread and rapid adoption of extended interval cervical cancer screening is possible, at least in this managed care setting. Further research examining multilevel drivers promoting or restricting extended interval screening across diverse healthcare settings is needed.

LanguageEnglish (US)
Pages44-50
Number of pages7
JournalPreventive Medicine
Volume109
DOIs
StatePublished - Apr 1 2018

Fingerprint

Cell Biology
Hispanic Americans
African Americans
Managed Care Programs
Early Detection of Cancer
Uterine Cervical Neoplasms
Medical Records
Guidelines
Delivery of Health Care
Research

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting. / Rendle, Katharine A.; Schiffman, Mark; Cheung, Li C.; Kinney, Walter K.; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas; Castle, Philip E.

In: Preventive Medicine, Vol. 109, 01.04.2018, p. 44-50.

Research output: Contribution to journalArticle

Rendle, Katharine A. ; Schiffman, Mark ; Cheung, Li C. ; Kinney, Walter K. ; Fetterman, Barbara ; Poitras, Nancy E. ; Lorey, Thomas ; Castle, Philip E. / Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting. In: Preventive Medicine. 2018 ; Vol. 109. pp. 44-50.
@article{e99a4d97d2344414a9ed199f628bbec7,
title = "Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting",
abstract = "Although guidelines have recommended extended interval cervical screening using concurrent human papillomavirus (HPV) and cytology (“cotesting”) for over a decade, little is known about its adoption into routine care. Using longitudinal medical record data (2003–2015) from Kaiser Permanente Northern California (KPNC), which adopted triennial cotesting in 2003, we examined adherence to extended interval screening. We analyzed predictors of screening intervals among 491,588 women undergoing routine screening, categorizing interval length into early (< 2.5 years), adherent (2.5 < 3.5 years), or late (3.5 < 6.0 years). We also examined repeated early screening in a subgroup of 50,691 women. Predictors examined included: cohort year (defined by baseline cotest, 2003–2009), race/ethnicity, and baseline age. Compared to the 2003 cohort, women in the 2009 cohort were significantly less likely to screen early (aOR = 0.22, 95{\%} CI = 0.21, 0.23) or late (aOR = 0.47, 95{\%} CI = 0.45, 0.49). African American (AA) and Hispanic women were less adherent overall than Non-Hispanic White women, with increased early [(AA: aOR = 1.21, 95{\%}CI = 1.17, 1.25) (Hispanic: aOR = 1.08, 95{\%}CI = 1.06, 1.11)] and late screening [(AA: aOR = 1.23, 95{\%}CI = 1.19, 1.27) (Hispanic: aOR = 1.06, 95{\%}CI = 1.03, 1.08)]. Asian women were slightly more likely to screen early (aOR = 1.03, 95{\%}CI = 1.01, 1.05), and less likely to screen late (aOR = 0.92, 95{\%} CI = 0.90, 0.94). Women aged 60–64 years were most likely to screen early for two consecutive intervals (aOR = 2.09, 95{\%}CI = 1.91, 2.29). Our study found that widespread and rapid adoption of extended interval cervical cancer screening is possible, at least in this managed care setting. Further research examining multilevel drivers promoting or restricting extended interval screening across diverse healthcare settings is needed.",
author = "Rendle, {Katharine A.} and Mark Schiffman and Cheung, {Li C.} and Kinney, {Walter K.} and Barbara Fetterman and Poitras, {Nancy E.} and Thomas Lorey and Castle, {Philip E.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.ypmed.2017.12.023",
language = "English (US)",
volume = "109",
pages = "44--50",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting

AU - Rendle, Katharine A.

AU - Schiffman, Mark

AU - Cheung, Li C.

AU - Kinney, Walter K.

AU - Fetterman, Barbara

AU - Poitras, Nancy E.

AU - Lorey, Thomas

AU - Castle, Philip E.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Although guidelines have recommended extended interval cervical screening using concurrent human papillomavirus (HPV) and cytology (“cotesting”) for over a decade, little is known about its adoption into routine care. Using longitudinal medical record data (2003–2015) from Kaiser Permanente Northern California (KPNC), which adopted triennial cotesting in 2003, we examined adherence to extended interval screening. We analyzed predictors of screening intervals among 491,588 women undergoing routine screening, categorizing interval length into early (< 2.5 years), adherent (2.5 < 3.5 years), or late (3.5 < 6.0 years). We also examined repeated early screening in a subgroup of 50,691 women. Predictors examined included: cohort year (defined by baseline cotest, 2003–2009), race/ethnicity, and baseline age. Compared to the 2003 cohort, women in the 2009 cohort were significantly less likely to screen early (aOR = 0.22, 95% CI = 0.21, 0.23) or late (aOR = 0.47, 95% CI = 0.45, 0.49). African American (AA) and Hispanic women were less adherent overall than Non-Hispanic White women, with increased early [(AA: aOR = 1.21, 95%CI = 1.17, 1.25) (Hispanic: aOR = 1.08, 95%CI = 1.06, 1.11)] and late screening [(AA: aOR = 1.23, 95%CI = 1.19, 1.27) (Hispanic: aOR = 1.06, 95%CI = 1.03, 1.08)]. Asian women were slightly more likely to screen early (aOR = 1.03, 95%CI = 1.01, 1.05), and less likely to screen late (aOR = 0.92, 95% CI = 0.90, 0.94). Women aged 60–64 years were most likely to screen early for two consecutive intervals (aOR = 2.09, 95%CI = 1.91, 2.29). Our study found that widespread and rapid adoption of extended interval cervical cancer screening is possible, at least in this managed care setting. Further research examining multilevel drivers promoting or restricting extended interval screening across diverse healthcare settings is needed.

AB - Although guidelines have recommended extended interval cervical screening using concurrent human papillomavirus (HPV) and cytology (“cotesting”) for over a decade, little is known about its adoption into routine care. Using longitudinal medical record data (2003–2015) from Kaiser Permanente Northern California (KPNC), which adopted triennial cotesting in 2003, we examined adherence to extended interval screening. We analyzed predictors of screening intervals among 491,588 women undergoing routine screening, categorizing interval length into early (< 2.5 years), adherent (2.5 < 3.5 years), or late (3.5 < 6.0 years). We also examined repeated early screening in a subgroup of 50,691 women. Predictors examined included: cohort year (defined by baseline cotest, 2003–2009), race/ethnicity, and baseline age. Compared to the 2003 cohort, women in the 2009 cohort were significantly less likely to screen early (aOR = 0.22, 95% CI = 0.21, 0.23) or late (aOR = 0.47, 95% CI = 0.45, 0.49). African American (AA) and Hispanic women were less adherent overall than Non-Hispanic White women, with increased early [(AA: aOR = 1.21, 95%CI = 1.17, 1.25) (Hispanic: aOR = 1.08, 95%CI = 1.06, 1.11)] and late screening [(AA: aOR = 1.23, 95%CI = 1.19, 1.27) (Hispanic: aOR = 1.06, 95%CI = 1.03, 1.08)]. Asian women were slightly more likely to screen early (aOR = 1.03, 95%CI = 1.01, 1.05), and less likely to screen late (aOR = 0.92, 95% CI = 0.90, 0.94). Women aged 60–64 years were most likely to screen early for two consecutive intervals (aOR = 2.09, 95%CI = 1.91, 2.29). Our study found that widespread and rapid adoption of extended interval cervical cancer screening is possible, at least in this managed care setting. Further research examining multilevel drivers promoting or restricting extended interval screening across diverse healthcare settings is needed.

UR - http://www.scopus.com/inward/record.url?scp=85041386970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041386970&partnerID=8YFLogxK

U2 - 10.1016/j.ypmed.2017.12.023

DO - 10.1016/j.ypmed.2017.12.023

M3 - Article

VL - 109

SP - 44

EP - 50

JO - Preventive Medicine

T2 - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

ER -